-+ 0.00%
-+ 0.00%
-+ 0.00%
Beam Therapeutics announces press release availability
Share
Listen to the news
Beam Therapeutics announces press release availability
  • Beam Therapeutics announced it will present updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at ERS Congress 2026.
  • Late-breaking oral presentation scheduled for Sept. 8, 2026 in Barcelona; Beam plans a 7:00 a.m. ET investor webcast via https://www.beamtx.com.
  • Update comes as Beam prepares to initiate a pivotal cohort for BEAM-302, its lead liver-targeting genetic disease program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230700PRIMZONEFULLFEED9766769) on July 23, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending